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High levels of serum interleukin-8 (IL-8) have been detected in chronic hepatitis B (CHB) patients during
episodes of hepatitis ﬂares. We investigated whether hepatitis B virus (HBV) may directly induce IL-8
production and whether IL-8 may antagonize interferon-alpha (IFN-α) antiviral activity against HBV. We
showed that CHB patients had signiﬁcantly higher IL-8 levels both in serum and in liver tissue than
controls. In HBV-replicating HepG2 cells, IL-8 transcription was signiﬁcantly activated. AP-1, C/EBP and
NF-kB transcription factors were concurrently necessary for maximum IL-8 induction. Moreover, HBx
viral protein was recruited onto the IL-8 promoter and this was paralleled by IL8-bound histone
hyperacetylation and by active recruitment of transcriptional coactivators. Inhibition of IL-8 increases the
antiviral activity of IFN-α against HBV. Our results indicate that HBV activates IL-8 gene expression by
targeting the epigenetic regulation of the IL-8 promoter and that IL-8 may contribute to reduce HBV
sensitivity to IFN-α.
& 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Hepatitis B virus (HBV) infection is a major health problem world-
wide with estimates of nearly 400 million people currently infected
(Dienstag, 2008). HBV infectionmay associate with a large spectrum of
clinical forms, ranging from very mild and asymptomatic clinical
pictures to the most severe liver diseases, including fulminant
hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) (Dienstag,
2008).Chronic HBV infection is a dynamic condition in which the
interaction between virus and the host immune response inﬂuencesr Inc.
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Open access under CC BY-NC-NDthe outcome of the disease. Its natural history is complex and variable.
It includes different – not always sequential – phases that are
distinguishable on the basis of the presence in the serum of HBV “e”
antigen (HBeAg) or its antibody (anti-HBe), of the HBV DNA serum
levels, of alanine aminotransferases (ALT) values and of the liver
histology (EASL, 2012). The anti-HBe positive phase may be character-
ized by persistently low viremia levelso2000 UI/ml), normal ALT and
minimal histological lesions (inactive chronic HBV carrier state) (EASL,
2012) or by stable or ﬂuctuating high levels of viral replication and ALT
values, with active liver necroinﬂammation (HBeAg-negative chronic
hepatitis). Patients with HBeAg-negative chronic hepatitis B (CHB)
may undergo recurrent, spontaneous “hepatic ﬂares,” characterized by
wide ﬂuctuations of viremia levels, liver inﬂammation and a propen-
sity to a rapid progression towards cirrhosis (EASL, 2012).
The HBV replication cycle is not directly cytotoxic to cells and
the pathogenesis of liver disease has conventionally been attrib-
uted to cytolytic killing of infected hepatocytes by virus-speciﬁc T
cell response (Chisari and Ferrari, 1995; Perrillo, 2001). However,
important data have shown that the high frequencies of HBV-
speciﬁc CD8+ T cells in patients with chronic HBV infection are
associated with HBV control rather than with hepatic injury license.
Table 1
Characteristics of patients with HBV-related chronic liver disease (CLD) and control subjects.
Parameter Patients with HBV-related CLD Control subjectsa P value
(n¼26) (n¼22)
Age (years), median (range) 41 (29–84) 42 (20–60) NS (0.987)
Male sex, n (%) 21 (80.8) 13 (59) NS (0.150)
ALT (IU/L), median (range) 100 (50–260) 18 (10–38) o 0.0001
Intrahepatic IL–8 mRNA Rel.C. (fold), median (range) 0.71 (0.01–4.9) 0.06 (0.01–0.07) 0.003
Serum IL–8 (pg/mL), median (range) 29.5 (7.7–278.3) 10.5 (2–5) o 0.0001
Abbreviations: ALT, alanine aminotransferases; Rel. C., Relative Concentration; HBV, hepatitis B virus.
a None of the 22 control subjects had any sign of liver disease, seven of them were inactive HBV carriers and 15 were individuals negative for all HBV serum markers.
Fig. 1. Chronic hepatitis B (CHB) patients have signiﬁcantly higher amounts of IL-8 mRNA in the liver and of IL-8 chemokine in the serum than control subjects.
(A) Intrahepatic amounts of IL- 8 mRNA. (B) Serum IL-8 levels. Median relative amounts of IL-8 mRNA in the liver of CHB patients (n¼14) and of control subjects (n¼5) were
0.71 (range: 0.01–4.9) and 0.06 (range: 0.01–0.079), respectively, whereas median levels of IL-8 chemokine in the serum of CHB patients (n¼26) and of control subjects
(n¼22) were 29.5 pg/mL (range: 7.7–278.3 pg/mL) and 10.5 pg/mL (range: 2–20 pg/mL), respectively.
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In addition, it has been demonstrated that adoptive transfer of
HBsAg-speciﬁc CD8+ T cells in HBV transgenic mice results in the
rapid recruitment of HBV-non-speciﬁc bystander lymphocytes and
that liver damage becomes manifest when non-speciﬁc,
chemokine-mediated recruitment of neutrophils, natural killer
(NK) cells and activated T-cells occurs (Kakimi et al., 2001; Sitia
et al., 2004). Of interest, it has been recently shown that in chronic
HBV infected patients ﬂares of liver inﬂammation (either sponta-
neous or induced by anti-viral withdrawal) are preceded by a
parallel increase of interleukin-8 (IL-8) production and serum HBV
DNA levels (Dunn et al., 2007; Tan et al., 2010). IL-8 may synergize
with interferon- alpha (IFN-α) to activate NK cells, (Dunn et al.,
2007) and very recent data have shown that HBV-speciﬁc T cells
maturing in the intrahepatic inﬂammatory environment can
produce IL-8, which in turn can contribute to the development
of liver damage through the recruitment of granulocytes (Gehring
et al., 2011; Zimmermann et al., 2011).
IL-8 is a CXC chemokine able to elicit granulocytes, NK cells and T
cell chemotaxis at the inﬂammatory site (Mukaida, 2003; Taub et al.,
1996). It is a principal mediator of the inﬂammatory response to many
viruses and bacteria (Girard et al., 2002; Green et al., 2006; Hisatsune
et al., 2008; Polyak et al., 2001a, 2001b; Rajaiya et al., 2008; Venza
et al., 2007; Wagoner et al., 2007; Yu et al., 2011; Zheng et al., 2008)
and it may interfere with the antiviral effect of IFN-α (Girard et al.,
2002; Khabar et al., 1997a; Lee et al., 2011; Polyak et al., 2001a, 2001b).
Previous data had demonstrated that the HBV-encoded regulatory
HBX protein is able to transactivate the IL-8 promoter (Mahe et al.,
1991). However, the exact mechanisms through which HBV is able to
induce IL-8 gene expression remain mostly unknown.
In the present study we investigated IL-8 in the course of HBV
infection and for this purpose we quantiﬁed the IL-8 amounts in
paired serum and liver tissue samples of chronic HBV infectedindividuals either CHB or inactive carriers. Moreover, by using a
cell-based HBV replication system that makes it possible to
recapitulate the HBV replication cycle including the nuclear gen-
eration of covalently closed-circular DNA (cccDNA) molecules
(Pollicino et al., 2006), we studied the molecular mechanisms
implicated in the activation of IL-8 gene expression and veriﬁed
whether IL-8 might reduce HBV sensitivity to IFN-α.Results
IL-8 amounts in liver tissues and sera of CHB patients, inactive HBV
carriers and HBV-neg subjects
Real-time PCR analysis on liver tissue specimens showed that
CHB patients had signiﬁcantly higher median amounts of IL-8
mRNA (0.71 [range: 0.01–4.9] versus 0.06 [range: 0.01–0.07];
P¼0.003) compared with the subjects of the control group,
including both inactive HBV carriers (IBC) and HBV-neg subjects
(Table 1 and Fig. 1A). Moreover, among CHB patients intrahepatic
IL-8 mRNA levels were signiﬁcantly higher in HBeAg-negative
patients (1.7 [range: 0.5–4.7] versus 0.1 [range: 0.01–4.9];
P¼0.028) than in HBeAg-positive ones. Both HBeAg-negative and
HBeAg-positive CHB patients had much higher amounts of IL-8
mRNA in the liver than controls (P¼0.004 and P¼0.015, respec-
tively). Concentrations of circulating IL-8 chemokine, assayed by a
quantitative ELISA kit, were also signiﬁcantly increased in CHB
patients compared with controls (median, 29.5 pg/mL [range: 7.7–
278.3 pg/mL] versus 10.5 pg/mL [range: 2–20 pg/mL], respectively;
Po0.0001) (Table 1 and Fig. 1B) and this statistical signiﬁcance
was maintained also when serum IL-8 amounts in CHB patients
were separately compared with the amounts in IBC (median,
9.78 pg/mL; range, 4.2–19.9 pg/mL; Po0.0001) and in HBV-neg
Fig. 2. HBV replication is associated with signiﬁcantly increased amounts of IL-8 transcripts in transfected HepG2 cells. (A) At 48 h after transfectionwith 0.5 mg of linear HBV
genomes (WTHBV-D: HBV of genotype D; WTHBV-A: HBV of genotype A) or 0.5 mg of pcDNA3 empty vector, total RNA was extracted from HepG2 cells and IL-8 mRNA
quantiﬁcation was performed by speciﬁc real-time PCR. (B) Transfection of increasing amounts of HBV DNA (WTHBV-A) induces a parallel increment of IL-8 transcript
production (up to 10-fold). (C) Southern blot analysis of HBV replicative intermediates. Lanes correspond to DNA extracted from cytoplasmic HBV core particles derived from
HepG2 cells that were transfected with increasing amounts of monomeric linear WT HBV genomes. Cells were harvested at 48 h post-transfection. Membranes were exposed
to an X-ray ﬁlm for autoradiography at 80 1C for 4 h. (D) Northern blot analysis of HBV transcripts isolated from HepG2 cells at 48 h after transfection with increasing
amounts of monomeric linear HBV genomes. Membranes were exposed to an X-ray ﬁlm for autoradiography at 80 1C for 24 h. Lanes correspond to pregenomic (pg), PreS1,
and PreS2/S viral messenger RNA (mRNA). RNA loading was controlled by rehybridization with a 32P-labeled 18S speciﬁc probe. (E) Expression proﬁle of IL-8 in HepG2 cells
transfected with increasing amounts of pcHBx, (F) with equal increasing amounts of the HBx-mutant viral genome, mutHBxHBV-A, or (G) cotransfected with increasing
amounts of mutHBxHBV-A genome along with 0.2 mg of pcHBx. All experiments were performed in duplicate and the results are the average of three independent
experiments (mean7SD). Abbreviations: OC, open circular HBV DNA; DS, double-stranded HBV DNA; SS, single–stranded HBV DNA.
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control group. Instead, no statistically signiﬁcant difference was
found between serum concentrations of IL-8 chemokine in HBeAg-
negative and HBeAg-positive CHB patients (median, 31.5 versus
28 pg/mL, respectively; P¼0.637). As expected, serum HBV DNA
levels were signiﬁcantly higher in CHB patients (median,
3.2106 IU/mL; range, 2.1104–1.7108 IU/mL) compared with
levels detected in IBC (median, 6.6102 IU/mL; range, 12–
1.8103 IU/mL; Po0.0001). Of note, a signiﬁcant correlation
was found between serum IL-8 concentrations and HBV DNA
amounts (r¼0.519; P¼0.002) in HBV infected individuals.
IL-8 expression Is upregulated in HBV-replicating hepatoma cell line
We have shown that transient transfection of plasmid free
linear HBV DNA into HepG2 or Huh7 cell lines makes it possible to
recapitulate the HBV replication cycle, including the nuclear
generation of viable cccDNA (Pollicino et al., 2006). Thus, to
investigate the role of HBV in the induction of IL-8 expression,
HepG2 cells were transiently transfected either with 0.5 mg of
linear wild-type (WT) HBV DNAs of genotype D or genotype A
(WTHBV-D and WTHBV-A, respectively) or with pcDNA3.1 empty
vector as a control at 24 h postplating. Total RNA was extracted at48 h after transfection, and expression of IL-8 was analyzed by
quantitative real-time PCR. As shown in Fig. 2A, the replication of
HBV (both of genotype D and A) in HepG2 cells was associated
with a signiﬁcant increase of IL-8 transcription (P¼0.038 and
P¼0.046, respectively) when compared with the control cells.
Moreover, when increasing amounts (0.1, 0.2, 0.5 and 1 mg) of
WTHBV-D or WTHBV-A were transfected, higher amounts of viral
replicative intermediates and transcripts were produced in a dose-
dependent manner (Fig. 2C, D) and these events were paralleled
by an increased production of IL-8 transcripts (Fig. 2B). In addition,
to analyze the contribution of HBx viral regulatory protein in the
induction of IL-8 gene expression, HepG2 cells were transfected
with the same increasing amounts of either the pcHBx recombi-
nant vector or of the mutHBxHBV-A genome that does not express
HBx because of a stop codon for amino acid 8 of the HBx open
reading frame (Belloni et al., 2009). Furthermore, to assess the
pattern of IL-8 expression when the X protein is provided in trans
to the HBx-mutant HBV, HepG2 cells were cotransfected with
mutHBxHBV-A genome and pcHBx vector. Real-time PCR quanti-
ﬁcations showed that IL-8 mRNA amounts were increased up to
threefold in cells expressing HBx and up to fourfold in cells
replicating the mutHBxHBV-A genome than in cells transfected
with an empty vector (Fig. 2E, F). Thus, though IL-8 mRNA levels in
Fig. 3. The IL-8 promoter is activated by HBV. (A) HepG2 cells were cotransfected with 0.5 mg of a reporter plasmid containing 1.4 kb of the IL-8 promoter (wtIL-8 LUC) along
with 0.1, 0.2, 0.5 or 1 mg of monomeric linear HBV genomes (both WTHBV-D and WTHBV-A were used), (B) 0.1, 0.2, 0.5 or 1 mg of monomeric linear mutHBxHBV-A or of
WTHBV-A genomes, (C) 0.1, 0.2, 0.5 or 1 mg of pcHBx expression vector, (D) 0.1, 0.2, 0.5 or 1 mg of mutHBxHBV-A and 0.2 mg of pcHBx. The basal activity of cells cotransfected
with the wtIL-8 LUC reporter and empty vectors was set at1 (Control). Luciferase activities were determined 48 h after transfection, and the results are the average of three
independent experiments carried out in duplicate. Means 7S.D. are presented.
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WTHBV-A transfected cells, they were higher compared to control
cells, indicating that, aside from HBx, other viral factors are
implicated in HBV-mediated IL-8 induction. Interestingly, in
HepG2 cotransfected with mutHBxHBV-A genome and pcHBx
vector IL-8 mRNA amounts were comparable to those detected
in WTHBV-A replicating cells (Fig. 2G).
Transactivation of the IL-8 promoter by HBV
The impact of HBV transcription/replication on IL-8 promoter
activity was investigated by using the HBV cccDNA-driven replica-
tion system (Pollicino et al., 2006). A 1.4-kb IL-8 promoter-
luciferase construct (wtIL-8 LUC) was transfected into HepG2 cells
along with increasing amounts of WTHBV-A, WTHBV-D, or
mutHBxHBV-A genomes or of pcHBx vector. Measurement of IL-
8 promoter-mediated luciferase activity in HBV-replicating cells
showed that both genotype A and D WT HBV genomes were able
to stimulate basal IL-8 promoter activity up to 100-fold in a dose-
dependent manner (Fig. 3A), whereas transfection of equal
amounts of mutHBxHBV-A virus led to signiﬁcantly lower activa-
tion of the IL-8 promoter (up to 30-fold; Po0.0001) (Fig. 3B). HBx
expression stimulated the basal IL-8 promoter activity up to
threefold when 0.2 mg of the pcHBx were transfected (Fig. 3C).
Moreover, when the HBx-mutant virus was trans-complemented
with the wild type HBx gene, in co-transfection experiments, its
ability to transactivate the IL-8 promoter was again largely
restored (Fig. 3D).
Subsequently, to determine the minimal IL-8 promoter
domains required for HBx and HBV-mediated transcriptional
activation, a series of IL-8 reporter gene constructs containing
mutated AP-1, C/EBP or NF-kB transcription factor binding sites
were utilized (Caristi et al., 2005; Venza et al., 2007). In
accordance with previously reported results, we found that
HBx-induced transcriptional activation of the IL-8 promoterrequires intact C/EBP and NF-kB binding sites (Fig. 4A). In HBV
replicating cells, mutation in the AP-1, in the C/EBP or in the
NF-kB binding sites reduced promoter activity by ∼50%, ∼40%
and ∼46% respectively (Fig. 4B). These data indicate that all
three binding sites, NF-kB, C/EBP, and AP-1, are involved in
HBV-induced IL-8 promoter activity.
To determine signal pathways implicated in HBV-mediated
transcriptional activation of the IL-8 gene, HBV-replicating cells
and control cells were treated with inhibitors of PI3K/Akt
(LY294002), p38 MAPK (SB203580), JNK (JNKi II), IkB kinase (Bay
11-7082), Erk (PD98059), SRC tyrosine kinase (PP2) and AP-1
(Tanshinone IIA) for 16 h. As shown in Fig. 4C, treatment of HBV
replicating-cells with Bay 11-7082 (10 μM) or Tanshinone IIA
(25 μM) completely abolished the IL-8 promoter-mediated lucifer-
ase activity, whereas treatment with LY294002 (30 μM), SB203580
(25 μM) or JNKi II (25 μM) only partially inhibited IL-8 promoter
activation. PD98059 and PP2 treatments did not signiﬁcantly affect
HBV-mediated promoter activity (data not shown). Moreover, the
ELISA assay showed that Bay 11-7082 or Tanshinone IIA was able
to strongly reduce (up to 90% and 85%, respectively) HBV-
mediated IL-8 production. (Fig. 4D). Treatments with LY294002,
SB203580 or JNKi II reduced IL-8 production by 55%, 60% and 45%,
respectively, (Fig. 4D). These last data conﬁrm the importance of
NF-kB and AP1 pathways in the induction of IL-8 expression by
HBV and indicate that PIK3/AKT, p38 MAPK and JNK signaling
pathways also have a role in this induction.
The analysis of the expression of a selected number of genes by
TaqMan Low-Density Arrays in HBV-replicating cells and control
cells conﬁrmed the ability of HBV to signiﬁcantly induce the
production of IL-8 transcripts and, consistently, showed that viral
replication may induce the upregulation of numerous genes (as,
NFKB1, IKKB, IL1B, TNFα, TNFRSF1A, TBK1 IRAK1, IRAK4, TRAF6,
PIK3CB, PIK3R2, CREB, JUN, ATF4, MAPK11 and MAPK13) (Fig. 4E).
involved – directly or indirectly – in the activation the IL-8
promoter (Hoffmann et al., 2002).
Fig. 4. AP-1, C/EBP and NF-kB binding sites are all involved in HBV-induced IL-8 promoter activation. (A) Identiﬁcation of the minimal domains required for HBx- and
(B) HBV-induced IL-8 promoter transactivation. HepG2 cells were cotransfected with the indicated reporter plasmids (a series of mutated IL-8 reporter gene constructs) and
0.2 mg of pcHBx expression vector or 0.5 mg of monomeric linear HBV genomes (WTHBV-A). At 48 h posttransfection, the luciferase assay was performed. The basal activity of
cells cotransfected with the wtIL-8 LUC reporter and empty vectors was set at1. The HBx- and HBV-induced fold activation for each IL-8 reporter plasmid is provided.
(C) HepG2 cells were cotransfected with 0.5 mg of wtIL-8 LUC reporter and 0.5 mg of monomeric linear HBV genomes (WTHBV-A) or 0.5 mg of empty pcDNA3.1 vector and
treated with DMSO (Vehicle) or inhibitors of IkB kinase (Bay 11-7082: 10 μM), AP-1 (Tanshinone IIA: 25 μM), PI3K/Akt (LY294002: 30 μM), p38 MAPK (SB203580: 25 μM) and
JNK (JNKi II; 25 μM). Cells cotransfected with 0.5 mg of wtIL-8 LUC reporter and 0.5 mg of WTHBV-A or 0.5 mg of empty vector and treated with DMSO (Vehicle) were used as a
negative control (Control). At 16 h post-treatment, cells and supernatants were harvested to test luciferase activity by luciferase reporter assay and (D) IL-8 production by
ELISA test, respectively. All experiments were performed in duplicate and repeated at least three times. Means 7S.D. are presented. (E) Expression proﬁling of selected genes
in HBV replicating HepG2 cells. Custom real-time PCR liquid arrays (TLDAs-Applied Biosystems) were loaded with 0.2 mg of cDNA obtained from total RNA extracted from
HepG2 cells at 48 h posttransfection with 0.5 mg of monomeric linear HBV genomes (WTHBV) or 0.5 mg empty pcDNA3.1 vector. Results are expressed as fold induction over
the basal level of expression of empty vector transfected cells that was set at 1. Experiments were performed in duplicate and the results are the average of three
independent experiments (mean7SD).
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tissues of chronic HBV carriers and in HBV-replicating HepG2 cells
It is known that HBV may induce epigenetic changes in host
cells and HBx seems to play a central role in these epigenetic
modiﬁcations. (Herceg and Paliwal, 2011; Paschos and Allday,
2010) Indeed, it has been shown that this protein may interact
with different components of epigenetic complexes and may
induce a modulation of transcriptional activity of several target
genes (Kew, 2011; Park et al., 2007).
To analyze the recruitment of chromatin-modifying enzymes onto
the IL-8 gene promoter, we applied the ChIP assay to HBV-replicating
cells and liver tissues from two CHB patients, two IBC and two HBV-
neg subjects. Chromatin was immunoprecipitated using antibodiesthat speciﬁcally recognize acetylated histone H4, the acetyltrans-
ferases PCAF and p300, the histone deacetylase HDAC1 and HBx viral
protein. As shown in Fig. 5, histone H4 bound to the IL-8 promoter
was highly acetylated and the transcriptional coactivators PCAF and
p300 as well as HBx were recruited onto the IL-8 promoter both in
HepG2 cells replicating HBV and in liver tissues from CHB patients
with high viral loads. Interestingly, in IBC (subjects characterized by a
state of persistently low HBV replication) the HDAC1 histone deace-
tylases was recruited onto the IL-8 promoter. HADC1 recruitment in
these subjects was paralleled by the reduced binding to IL-8 of HBx
viral protein, p300 and PCAF co-activators and by the presence of
variable levels of IL8-bound histone acetylation. As expected, no HBx
recruitment onto the IL-8 promoter could be detected in HBV-neg
subjects. Moreover, in these subjects the recruitment on the IL-8
Fig. 5. HBV modulates the epigenetic control of IL-8 promoter activity by affecting the recruitment of chromatin modifying enzymes. Chromatin from empty vector
transfected-cells, HBV-transfected HepG2 cells and liver tissues from two chronic hepatitis B (CHB) patients, two inactive HBV carriers (IBC) and two HBV-negative
(HBV-neg) subjects, was immunoprecipitated with control IgG or speciﬁc anti-AcH4, anti-HDAC1, anti-p300, anti-PCAF, and anti-HBx antibodies and analyzed by PCR with
IL-8 promoter selective primers. All experiments were repeated at least twice (upper panel). Signal intensity of bands was quantiﬁed with Quantity One 1-D Analysis
Software (BioRad Laboratories). Data are expressed as relative arbitrary units (lower panel).
T. Pollicino et al. / Virology 444 (2013) 317–328322promoter of PCAF, and p300 acetyltransferase was highly reduced and
the binding of HDAC1 was associated with the hypoacetylation status
of H4 histone. Thus, in HBV infected patients the differential recruit-
ment of coactivators and corepressors onto the IL-8 promoter
appeared to be correlated with HBV replication activity.
Altogether, these results indicate that HBx viral regulatory
protein produced during HBV replication in the infected hepato-
cytes is recruited onto the IL-8 promoter and that its recruitment
is associated with IL-8 gene expression.
IL-8 impairs IFN alpha-inhibition of HBV replication
It has been shown that IL-8 may inhibit in vitro the antiviral
action of IFN-α (Khabar et al., 1997a) and an inverse correlation has
been found between serum IL8 levels and the sensitivity to
interferon treatment among patients infected with hepatitis C
virus (Lee et al., 2011; Polyak et al., 2001b).
By the use of the cell-based HBV replication system, we veriﬁed
whether IL-8 might weaken the action of IFN-α against HBV. Thus,
HBV replication was examined in HepG2 cells co-transfected with
HBV genomes and IL-8 siRNA (or siRNA-control) and then exposedor not to IFN-α treatment. Results from the ELISA assay ascertained
that IL-8 protein released in the supernatants of transfected cells
was signiﬁcantly reduced by treatment with siRNA-IL-8 but not
affected by siRNA-control (Fig. 6A).
Results from both Southern and Northern blotting showed that
siRNA-directed inhibition of IL-8 expression improved the efﬁcacy
of IFN-α treatment against HBV (Fig. 6D and E, respectively).
Indeed, HBV/IL8-siRNA co-transfected HepG2 cells showed a
stronger reduction of both HBV replicative intermediates
(Fig. 6D) and viral transcripts (Fig. 6E) compared to cells
co-transfected with HBV genomes and siRNA-control, after IFN-α
treatment. Interestingly, even in the absence of IFN-α treatment
the suppression of IL-8 in HBV/IL8-siRNA co-transfected cells
induced a reduction of the steady-state amounts of capsid asso-
ciated HBV DNA and of all the viral transcripts (Fig. 6B and C), thus
suggesting that IL-8 is able to induce HBV replication. To further
conﬁrm these results, viral transcription/replication was evaluated
in HBV transfected-cells pretreated or not pretreated with recom-
binant human IL-8 (rIL-8) and then exposed or not exposed to IFN-
α treatment. As shown in Fig. 6F and G, when HBV replicating-cells
were pretreated with rIL-8 (10 ng/mL), a signiﬁcant reduction of
Fig. 6. IL-8 weakens IFN-α antiviral action against HBV and induces viral transcription/replication in HBV-replicating HepG2 cells. (A) Determination of the effectiveness and speciﬁcity
of siRNA-IL-8 on IL-8 gene expression. HepG2 cells were transfected with empty pcDNA3.1 vector monomeric or with linear HBV genomes (WTHBV-A) alone or along with siRNA-
control or with siRNA-IL-8. IL-8 protein in culture supernatants was detected by ELISA. (B) Analysis of the effect of siRNA-IL-8 on HBV replication by Southern blotting of HBV replicative
intermediates at 48 h post transfection. (C) Analysis of the effect of siRNA-IL-8 on HBV transcription by Northern blotting of viral mRNAs from HepG2 cells 48 h after transfection with
WTHBV-A. (D) Southern blot analysis of HBV replicative intermediates from HepG2 cells transfected with WTHBV-A alone or co-transfected with WTHBV-A and IL-8 siRNA (or siRNA-
control) and then exposed or not to IFN-α IFN‐apha treatment (1000 U/ml) for 48 h. (E) Northern blot analysis of HBV transcripts extracted from HepG2 cells transfected withWTHBV-
A alone or co-transfected with WTHBV-A and IL-8 siRNA (or siRNA-control) and then exposed or not to IFN-α IFN-alpha treatment (1000 U/ml) for 48 h. (F) Southern blot analysis of
HBV replicative intermediates from HBV transfected-cells pretreated or not pretreated with recombinant human IL-8 (rIL-8) and exposed or not exposed to IFN-α treatment.
(G) Northern blot analysis of HBV transcripts isolated from HBV transfected-cells pretreated or not pretreated with recombinant human IL-8 (rIL-8) and exposed or not exposed to IFN-
α treatment. (H) Southern blot analysis of HBV replicative intermediates from HBV transfected-cells treated with increasing amount of rIL-8 (10-30 ng/ml). (I) Northern blot analysis of
HBV transcripts from HBV transfected-cells treated with equal increasing amount of rIL-8. In all panels densitometric quantiﬁcation of HBV replicative intermediates or of HBV
transcripts is shown. Signal intensity of the single-strand (SS) band underneath the linear double-stranded (DS) HBV DNA band or of pregenomic RNA (pgRNA) band was quantiﬁed
with Quantity One 1-D Analysis Software (BioRad Laboratories). Data are expressed as relative arbitrary units (mean7SD) from three independent experiments. Abbreviations: OC,
open circular HBV DNA; DS, double-stranded HBV DNA; SS, single-stranded HBV DNA.
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HBV transfected cells with rIL-8 in the absence of IFN-αwas able to
induce a dose dependent increase of HBV replication and tran-
scription (Fig. 6H and I).Discussion
The IL-8 chemokine is an important mediator of the innate
immunity with well-deﬁned immunomodulatory effects on T-cell
function and inﬂammatory response (Mukaida, 2003; Taub et al.,
1996). Recent evidence has suggested that this chemokine may
play an important role in the immunopathogenesis of HBV infec-
tion (Bertoletti et al., 2010). High levels of serum IL-8 have been
detected in CHB patients with active liver inﬂammation as well as
in patients with acute hepatitis B (but not in patients with other
acute viral infection) (Dunn et al., 2007; Gehring et al., 2011; Tan
et al., 2010; Zimmermann et al., 2011). Moreover, it has been
recently demonstrated that during the episodes of HBV reactiva-
tion, the increase of viremia levels is paralleled by an increment of
serum IL-8 amounts and that these events precede the onset of
hepatic ﬂare (Dunn et al., 2007; Tan et al., 2010).
In the current study, IL-8 was quantiﬁed in paired serum and
liver tissue samples from chronically HBV-infected and HBV-
negative subjects. Through this analysis, we found that in CHB
patients the presence of signiﬁcantly higher serum concentrations
of IL-8 chemokine was paralleled by an upregulation of IL-8 gene
expression in the paired liver specimens compared to controls,
suggesting that in CHB patients the high circulating amounts of IL-
8 are likely derived from the liver. We also found that HBeAg-
negative patients had signiﬁcantly higher levels of IL-8 transcripts
in the liver than HBeAg-positive patients, and this observation is
consistent with the fact that HBeAg-negative patients are much
more susceptible to ﬂares of liver inﬂammation associated with
rapid changes in HBV viremia levels than HBeAg-positive patients
(EASL, 2012). Our data are also in accordance with the body of
evidence indicating that HBeAg-positive infection is usually asso-
ciated with lower levels of pro-inﬂammatory cytokines and in
general with a more efﬁcient inhibition of the host's innate
immune response (Chen et al., 2004; Visvanathan et al., 2007;
Walsh and Locarnini, 2012).
By using a plasmid-free HBV transfection approach (Pollicino
et al., 2006), we were able to demonstrate that IL-8 gene
transcription is speciﬁcally induced in response to HBV replication
and that the increased amounts of IL-8 directly correlate with the
levels of HBV transcription/replication. In accordance with these
in vitro results, we also found a signiﬁcant correlation between IL-
8 chemokine concentrations and HBV viremia levels in the HBV
infected patients. Altogether, these data indicate that active HBV
replication is able to directly induce IL-8 production and provide
new evidence in support of an important role of the magnitude of
viral replication in the virus–host interplay, particularly in the
activation of the innate immune response (Ait-Goughoulte et al.,
2010; Bertoletti et al., 2010). It has been shown that the X protein
of HBV is able to transactivate IL-8 gene expression through NF-kB
and C/EBP-like cis-elements (Mahe et al., 1991). By the use of our
HBV replication system, we demonstrated that binding sites for
NF-kB, AP-1, and C/EBP are required for maximum HBV-induced
IL-8 promoter activity as well as for maximal IL-8 protein produc-
tion. In this context, our ﬁnding that in cells replicating HBx-
defective HBV the activation of IL-8 gene promoter was signiﬁ-
cantly reduced, but not abolished, suggests that other HBV gene
products might also be involved in the regulation of IL-8 gene
expression. This hypothesis is supported by available data showing
that in addition to HBx other viral proteins, such as the large and
middle envelope proteins or the core and HBe proteins, have theability to deregulate the cellular transcription program (Ait-
Goughoulte et al., 2010; Hildt et al., 2002; Locarnini et al., 2005).
Our results showing that CHB patients infected with HBeAg-
negative HBV had higher intrahepatic levels of IL-8 compared to
patients infected with HBeAg-positive viral strains further conﬁrm
our hypothesis. Thus, the control of IL-8 gene expression by HBV
appears to be complex and multifaceted with the involvement of
different signaling pathways, as also indicated by the results
obtained from the PCR arrays showing that HBV upregulates the
expression of a number of transcription factors and protein
kinases, which in principle have the ability to modulate NF-kB or
AP-1 activity. In addition, in our HBV replication system the
upregulation of IL-1 and TNF-alpha proinﬂammatory cytokines –
which are known to strongly induce IL-8 production (Hoffmann
et al., 2002) – indicates that different mechanisms synergize to
induce IL-8 overexpression during active HBV replication.
By the use of ChIP assay, we found that active HBV replication
was associated – both in vivo and in vitro – with a hyperacetyla-
tion status of IL8 promoter and with the recruitment on this
promoter of PCAF and p300 acetyltransferases as well as of the
HBx viral protein. Of interest, the presence of the class I deacety-
lase HDAC1 on the IL-8 promoter was associated with a low HBV
replication state in vivo indicating that HBV may exert an epige-
netic control of IL-8 gene by favouring the recruitment of chro-
matin modifying enzymes onto the IL-8 promoter. The HBx
regulatory protein might have an important role in this control
since it has been shown that it is able to interact directly with the
CREB-binding protein (CBP)/p300 to synergistically enhance its
activity and to modify chromatin dynamics of target genes (Cougot
et al., 2007). Altogether our results suggest that HBV might
actively contribute to the constitution of the “enhanceosome”-like
structure known to control IL-8 gene expression (Hoffmann et al.,
2002).
Cytokines and chemokines released in response to virus infec-
tions have the main role of recruiting inﬂammatory cells, of
constraining virus replication and spread, and of inducing adaptive
immunity (Biron, 2001; Guidotti and Chisari, 2000; Redpath et al.,
2001). However, when the production of chemokines (like IL-8) in
the context of viral infections is continuous it may become
harmful to the host (Luster, 1998; Mukaida, 2003). The existence
of a kind of vicious circle between IL-8 production and several viral
infections has been described (Alcorn et al., 2001; Girard et al.,
2002; Khabar et al., 1997a; Khabar et al., 1997b; Murayama et al.,
1994; Wagoner et al., 2007). It has been shown that human
cytomegalovirus (CMV) can induce IL-8 gene transcription in
various types of cells and that IL-8 may enhance human CMV
replication (Murayama et al., 1994). In the present study, we found
that IL-8 is able to induce HBV replication in a dose dependent
manner and that the induction of IL-8 gene expression by HBV is
also dose-dependent. These results suggest the presence of an
amplifying loop between IL-8 production and HBV activity, which
in part might explain both the ampliﬁcation of liver damage that
occurs during the phase of immune reactivation of HBV and the
difﬁculties in ﬁnding a temporal correlation between immunolo-
gical parameters and the kinetics of HBV viremia in the course of
hepatic ﬂares (Bertoletti et al., 2010).
Accumulating evidence indicates that IL-8 induced by viruses
may also contribute to counteract IFN-α antiviral action (Girard
et al., 2002; Lee et al., 2011; Polyak et al., 2001a, 2001b). Our
results showing that the speciﬁc inhibition of IL-8 increases the
potency of IFN-α against HBV in vitro and that the addition of
recombinant human IL-8 almost totally rescues HBV replication
during IFN challenge strongly suggest that IL-8 expression induced
by HBV can impair the ability of endogenous IFN-α to inhibit early
stages of viral replication, thus favoring viral persistence, and can
also contribute to the poor response to IFN-α treatment.
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indicating that viruses have evolved strategies to turn chemokine
activity to their own advantage (Alcami, 2003; Finlay and
McFadden, 2006; Kotwal et al., 2012). In that respect, the general
inﬂammatory microenvironment induced by HBV can be consid-
ered an effective stratagem for manipulating the host's immune
response to achieve viral persistence and the establishment
of CHB.
In conclusion, HBV is able to directly induce the production of
the IL-8 chemokine which in turn may contribute to the persis-
tence of the infection, to the pathogenesis of viral related liver
damage as well as to the mechanisms of resistance to IFN.
Consequently, inhibition of IL-8 production or activity could be
instrumental to the suppression of viral activity, to the reduction/
block of liver inﬂammation and to the improvement of IFN-α
antiviral action and it might open novel avenues for the develop-
ment of effective immunotherapeutic approaches against HBV.Materials and methods
Study Patients
We studied serum samples from 48 subjects who were seen in
the outpatient service of the Liver Unit at the Messina University
Hospital (Table 1). Twenty-six of the 48 subjects (23 men and
three women; mean age, 45717 years) had a histologically proven
HBV-related chronic liver disease whereas 22 (16 men and six
women; mean age, 37714.6 years) had no clinical, biochemical
and ultrasound signs of liver disease (control group). Of these 22
subjects, seven were inactive HBV carriers (IBC) –with persistently
serum HBV-DNA levelso2000 IU/mL and normal ALT (o40 U/L)
over a 10-year median period of follow-up – and 15 were
individuals negative for all HBV serum markers and without any
sign of liver disease (HBV-neg subjects).
Eight of the 26 CHB patients were HBV “e” antigen (HBeAg)
positive and 18 were HBeAg-negative and positive for the corre-
sponding antibody (anti-HBe). All the seven inactive HBV carriers
were HBeAg-negative/anti-HBe positive.
Frozen liver biopsies were available for molecular analyses
from 14 CHB patients (seven HBeAg-positive and seven anti-
HBeAg positive). In addition, frozen liver tissues were also avail-
able from ﬁve subjects of the control group, two inactive HBV
carriers and three HBV-neg individuals who underwent surgery
for benign liver tumor or metastasis from extra-hepatic tumors.
Liver samples from the control subjects were obtained from
unaffected areas of liver resections. All the subjects were negative
for hepatitis delta virus, hepatitis C virus and human immunode-
ﬁciency virus serum markers and all CHB patients were treatment-
naïve.
The study protocol was performed according to the principles
of the Declaration of Helsinki. The collection of blood and tissue
samples for research was approved by the ethics committee of the
University Hospital of Messina, Messina, Italy. Written informed
consent was obtained from all patients.
Chemicals and Antibodies
Phosphatidylinositol 3′ -kinase (PI3K)-Akt inhibitor LY294002,
p38 kinase inhibitor SB203580, c-Jun N-terminal kinase (JNK)
inhibitor JNKi II, mitogen-activated protein/ERK kinase/extracellu-
lar signal-regulated kinase (MEK) inhibitor PD98059, SRC tyrosine
kinase inhibitor PP2 and nuclear factor of kappa light polypeptide
gene enhancer in B-cell (NFkB) inhibitor BAY 11-7082 were from
Calbiochem-Novabiochem Corp (San Diego, CA, USA). The activator
protein-1 (AP-1) inhibitor Tanshinone IIA was from Enzo LifeSciences (Farmingdale, NY USA). Recombinant human CXCL8/IL-8
(208-IL) was from R&D SYSTEMS (Minneapolis, USA) and recom-
binant human IFN-α2b was from Schering-Plough Corporation
(Kenilworth, NJ, USA). Rabbit polyclonal antibody against AcH4
(IgG recognizing histone H4, which is tetra-acetylated at lysines 6,
9,13, and 17) (06-598) and rabbit polyclonal antibody against
HDAC1 (06-720) were from Upstate (Waltham, MA USA), rabbit
polyclonal antibody against p300 (sc-584) and rabbit polyclonal
antibody against PCAF (sc-8999) were from Santa Cruz Biotech-
nology (Santa Cruz, CA. USA), mouse monoclonal antibody against
HBx (MAI-081) was from Afﬁnity Bioreagent (Rockford, IL USA).
Plasmid Constructs and full-length HBV DNA Genomes
Plasmid constructs containing the full-length wild-type (wtIL-8
LUC) or truncated IL-8 promoters [IL-8 AP-1 mutant (IL-8-mAP1),
IL-8 C/EBP mutant (IL-8-mC/EBP), IL-8 NF-kB mutant (IL-8-mNF-
kB), and IL-8 double mutant for C/EBP and NF-kB (IL-8-C/EBP-
NFkB)] controlling the expression of the luciferase gene were
generated as described previously (Caristi et al., 2005; Venza
et al., 2007).
Monomeric linear full-length wild type (WT) and HBx mutant
HBV genomes of genotype A (WTHBV-A and mutHBxHBV-A,
respectively) were released from the pCR.HBV.A.EcoRI (Pollicino
et al., 2006) and pCR.mtHBx.A.EcoRI (Belloni et al., 2009) plasmids
using EcorRI-PvuI restriction enzymes (New England Biolabs
GmbH, Frankfurt, Germany). Monomeric linear full-length WT
HBV genome of genotype D (WTHBV-D) was released from pUC.
HBV.D plasmid using SapI restriction enzyme (New England
Biolabs) (Pollicino et al., 2006).
The X coding region of HBV genotype A was ampliﬁed by PCR
and the resulting 465 bp fragment (positions 1374–1838 on the
HBV map) was cloned into pcDNA3.1 HA cloning vector (Invitro-
gen, Milan, Italy) (pcHBx-HA). Cloned HBx coding region was
veriﬁed by sequencing.
IL-8 ELISA
Patients sera and supernatants of transfected cells were tested
for IL-8 using the BD OptEIA human IL-8 ELISA kit II (BD
Biosciences, San Jose, CA USA) where 100 μl of patient serum, cell
culture supernatant or standard dilutions were analyzed according
to the manufacturer's protocol. This assay has a lower limit of
detection of 0.8 pg/ml.
Cell lines, Transfections, Treatments and luciferase reporter Assays
The HepG2 cell line was maintained in Dulbecco's modiﬁed
Eagle's medium with 10% fetal bovine serum (Life Technologies,
Grand Island, NY USA), 1% penicillin/streptomycin, and 1% gluta-
mine (Sigma-Aldrich S.r.l., Milan, Italy). For reporter assays, semi-
conﬂuent cells in 60-mm-diameter Petri dishes were transiently
transfected with 0.5 mg of monomeric linear wild-type HBV
genomes (WTHBV-A, mutHBxHBV-A or WTHBV-D) or 0.2 mg the
pcHBX-HA expression vector and 0.5 mg of different pIL-8-LUC
constructs using the FuGENE transfection reagent (Roche, India-
napolis, IN). Luciferase activity was determined 48 h later. All
experiments were performed in duplicate and repeated at least
three times. For transfection control, cells were cotransfected with
the plasmid pRL-TK (Clontech, Mountain View, CA), which
expresses Renilla luciferase under the control of the thymidine
kinase promoter. Luciferase levels in cell lysates were determined
by using the Dual-Luciferase Reporter Assay System (Promega
Corp, Madison, WI). The total amount of transfected DNA was kept
constant by adding pcDNA3.1 vector.
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cell culture medium 24 h post-transfection. The carrier dimethyl
sulfoxide (DMSO) was added as control. The concentrations of
drugs used are as follows: SB203580 (25 μM), LY294002 (30 μM),
JNKi II (25 μM), Bay 11-7082 (10 μM) PD98059 (30 μM), PP2
(20 μM) and Tanshinone IIA (25 μM). At 16 h post-treatment, cells
and supernatants were harvested to test luciferase activity by
luciferase reporter assay and IL-8 production by ELISA test,
respectively.
For treatments with IFN-α, HepG2 cells were seeded in a 6-well
plate at a density of 2105/well and transfected 24 h later with
0.5 μg of monomeric linear WTHBV-A genomes or cotransfected
with 0.5 μg of WTHBV-A genomes and 40 mM of IL-8 small
interfering RNA (IL-8 siRNA: sc-39631, Santa Cruz Biotechnology)
by using Lipofectamine 2000 (Invitrogen). IFN-αwas used at a ﬁnal
concentration of 1000 IU/ml and was added directly to the culture
medium starting at 3 h after transfection. HepG2 cells transfected
with WTHBV-A genomes were also exposed to recombinant
human IL-8 (rIL-8) that was used either alone or in combination
with IFN-α at a ﬁnal concentration of 10 ng/ml. Recombinant rIL-8
was added to the culture medium at1 h after transfection. Cell
culture medium plus IFN-α and/or rIL-8 was changed 1 day after
transfection and cells were harvested at 48 h posttransfection. In
dose-response experiments, rIL-8 was used at concentrations of
10, 20 and 30 ng/ml. Transfection experiments included 0.5 μg of
pcGFP expression vector to assess transfection efﬁciency (range:
40–50%).
Puriﬁcation of core particles associated with HBV DNA from HBV-
replicating cells
To purify HBV DNA from intracellular core particles, transfected
cells were washed once with ice-cold PBS and lysed in 50 mM
Tris–HCl, pH 7.4, 1 mmol EDTA, and 1% NP-40. Nuclei were pelleted
by centrifugation for 1 min at 10,000 g. The supernatant was
adjusted to 100 mMMgCl2 and treated with 100 mg/ml of DNase
I for 30 min at 37 1C. The reaction was stopped by adding EDTA to a
ﬁnal concentration of 25 mM. Protein was digested with 0.5 mg/ml
proteinase K and 1% SDS for 2 h at 50 1C. Nucleic acids were
puriﬁed by phenol/chloroform (1:1) extraction and ethanol pre-
cipitation adding glycogen and examined by Southern blot follow-
ing standard procedures as previously described (Pollicino et al.,
2007).
HBV RNAs and cellular mRNA analysis
Total RNA was extracted from liver tissue specimens and
HepG2 cells at 48 h post-transfection with the TRIzol reagent (Life
Technologies) as recommended by the manufacturer. RNA con-
centration was measured using an ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE) at 260 nm. RNA quality
and quantity were monitored by ethidium bromide staining and
by UV absorbance.
Northern blot analysis was performed following standard
procedures as previously described (Pollicino et al., 2007). Radio-
active probes were prepared by random priming protocol, using
either full-length HBV DNA or 18S cDNA templates and 32P α-dCTP
(Amersham).
For quantiﬁcation of IL8 mRNA in liver specimens and trans-
fected HepG2 cells, 5 μg of extracted RNA for each sample were
treated with RQ1 RNase-free DNase (Promega, Madison, WI) for
1 h at 37 1C, and used as a template for ﬁrst-strand cDNA synthesis
with Transcriptor First Strand cDNA Synthesys kit (Roche, India-
napolis, USA) and oligo(dT) primers according to manufacturer's
protocol. Five ml of each cDNA were then quantiﬁed by real-time
PCR analysis using the following IL-8 mRNA speciﬁc primers andprobes: forward primer 5′-ATGACTTCCAAGCTGGCCGTG-3′, reverse
primer 5′-TTTGATAAATTTGGGGTGGAAAGG
TT-3′. FRET hybridization probes 5′-AGCCTTCCTGATTTCTG-
CAGCTCTGTGTGAAG-FL-3′, 5′-LC640-AGTTTTGCCAAGGAGTGCTAAA-
GAACTTAGATG-PH-3′. The LightCycler h-G6PDH housekeeping Gene
Set (Roche) was used to normalize the RNA samples. Real-time PCR by
the use of the “utility channel” of COBAS TaqMan 48 was performed as
follows: 95 1C for 10 min then 60 cycles of 95 1C for 30 s, 57 1C for
20 s, 72 1C for 20 s. The plasmid pCRII-IL-8, containing one copy of the
IL-8 coding sequence (nt 1 to 1551) was used as standard for IL-8
cDNA quantiﬁcation. The plasmid was digested with EcoRI (New
England Biolabs) and the IL-8 sequence was gel puriﬁed using the
Wizard SV Gel and PCR Clean-Up System (Promega, Madison, WI
USA). The concentration of puriﬁed IL-8 DNA was determined with
the ND-1000 spectrophotometer and the corresponding copy number
was calculated. A series of 10-fold dilutions of the plasmid pCRII-IL-8
was used as standard for IL-8 cDNA quantiﬁcation.
For gene expression analysis by TaqMan Low-Density Arrays
(TLDAs) (Applied Biosystems, Foster City, CA), total RNA from
transfected HepG2 cells was extracted using the RNeasy Mini kit
(Qiagen) according to the manufacturer's instruction. RNA (5 μg)
was reverse transcribed using the Transcriptor First Strand cDNA
Synthesys kit and 200 ng of each cDNAwere loaded in double on a
customized TLDA with 18S RNA used as control. TLDAs were run
on an ABI 7900HT Sequence detection system and, real-time PCR
data were collected and analyzed with the SDS2.2 software
(Applied Biosystems)
ChIP assays
Forty-eight hours after transfection with linear HBV monomers,
HepG2 cells were ﬁxed in 1% formaldehyde, resuspended in 1 ml
of ChIP lysis buffer (50 mM Tris–HCl, pH 8.0, 0.5% NP40, 1 mM
EDTA, and 100 mM NaCl) and incubated 10 min at 4 1C. The lysate
was centrifuged to pellet the nuclei. Isolated cross-linked nuclei
were extracted with a 20 mM Tris–HCl, pH 8.0, 3 mM MgCl2,
20 mM KCl buffer containing protease inhibitors, pelleted by
microcentrifugation, and lysed by incubation in SDS lysis buffer
(1% SDS, 10 mM EDTA, 50 mM Tris–HCl, pH 8.1) containing
protease inhibitors. The resulting chromatin solution was soni-
cated for 10 pulses of 45 s at 80% power to generate 300- to 1000-
bp DNA fragments using a Sonopuls HD 2070 Sonicator (Bandelin
electronic GmbH & Co. KG, Berlin, Germany). After microcentrifu-
gation, the supernatant was diluted 1:10 in a dilution buffer (0.01%
SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris–HCl, pH 8.1,
167 mM NaCl, containing protease inhibitors), precleared with
blocked Protein G Plus (Pierce, Rockford, IL USA), and divided into
aliquots. The chromatin was then subjected to immunoprecipita-
tion for 14–16 h at 4 1C using antibodies speciﬁc to AcH4, HDAC1,
p300, PCAF and HBx. Immunoprecipitation with non-speciﬁc
immunoglobulins (Santa Cruz Biotechnology) was included in
each experiment as a negative control. After the reverse cross-
linking step, immunoprecipitated chromatin was treated with
20 U Plasmid-safe DNase (Epicenter, Madison, WI) for 1 h at
37 1C to degrade contaminating HBV open circular species and
then subjected to PCR ampliﬁcation using the HBV P23 and HBV
P24 primers speciﬁc for the HBV cccDNA and encompassing the
precore/core promoter region of the viral genome (Pollicino et al.,
2004).
To perform ChIP assays on liver tissues from chronically HBV-
infected patients, liquid nitrogen frozen biopsy specimens (from
0.5 to 1.0 cm) were lysed at 4 1C in 500 μL homogenization buffer
(50 mM Tris–HCl, pH 8.0, 1 mM EDTA, 0.2% NP-40, 150 mM NaCl)
with a TissueRupter instrument (Qiagen, Hilden, Germany). Nuclei
were isolated by centrifugation and then ﬁxed in 1% formaldehyde
for 15 min at 4 1C. After sonication and dilution, the chromatin was
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bodies speciﬁc to acH4, HDAC1, p300, PCAF and HBx. Immunopre-
cipitations with nonspeciﬁc immunoglobulins (Santa Cruz
Biotechnology Inc.) were included in each experiment as a
negative control. After the reverse cross-linking step, immunopre-
cipitated chromatin was analyzed by PCR ampliﬁcation using
cccDNA-speciﬁc primers.
Statistical analysis
Continuous variables were reported as median (range) and
categorical variables as frequencies (percentages). A nonpara-
metric approach was used to examine variables showing the
absence of a normal distribution, as veriﬁed by the Kolmogorov–
Smirnov test. The interdependence between numerical variables
was performed by the use of the Spearman Rank correlation,
whereas the Mann–Whitney test was applied to perform compar-
isons of continuously distributed variables between two indepen-
dent groups. For in vitro experiments the non parametric ANOVA
was applied and the Kruskall Wallis test was used. Bar graphs were
plotted to show the mean7standard deviation (SD) of at least
three independent experiments. P values o0.05 were considered
as statistically signiﬁcant. Statistical analysis was performed with
SPSS version 12.0 software package (SPSS Inc, Chicago, IL).Acknowledgment
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